
Novartis will develop an experimental eye drug with ThromboGenics in a pact worth nearly $500 million. The deal has been …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

